Compare · ARVN vs CCCC

ARVN vs CCCC

Side-by-side comparison of Arvinas Inc. (ARVN) and C4 Therapeutics Inc. (CCCC): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both companies sit in the Health Care sector. ARVN focuses on Biotechnology: Pharmaceutical Preparations, while CCCC focuses on Biotechnology: Biological Products (No Diagnostic Substances).
  • ARVN is the larger of the two at $423.0M, about 1.3x CCCC ($325.7M).
  • ARVN has been more active in the news (9 items in the past 4 weeks vs 7 for CCCC).
  • ARVN has more recent analyst coverage (25 ratings vs 24 for CCCC).
MetricARVNCCCC
Company
Arvinas Inc.
C4 Therapeutics Inc.
Price
-
-
Market cap
$423.0M
$325.7M
1M return
-
-
1Y return
-
-
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
NASDAQ
NASDAQ
IPO
2018
2020
News (4w)
9
7
Recent ratings
25
24
ARVN

Arvinas Inc.

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Bayer AG, and Insilico Medicine, Inc. Arvinas, Inc. was incorporated in 2013 and is based in New Haven, Connecticut.

CCCC

C4 Therapeutics Inc.

C4 Therapeutics, Inc., a biopharmaceutical company, develops novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable degrader that is in preclinical stage targeting IKZF1/3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; and BRAF V600E to treat melanoma, non-small cell lung cancer, colorectal cancer, and other solid malignancies, as well as RET to treat lung cancer, sporadic medullary thyroid cancers, and other solid malignancies. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffman-La Roche Ltd.; Biogen, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Latest ARVN

Latest CCCC